文献速递眼底病与葡萄膜炎

视网膜下移植干细胞来源视网膜色素上皮治疗Stargardt病:一项I期临床试验

TRANSPLANTATION OF SUBRETINAL STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM FOR STARGARDT DISEASE: A Phase I Clinical Trial.
PubMed 文献 · Retina · 2023-01-01

这项前瞻性I期临床试验将人胚胎干细胞来源视网膜色素上皮细胞注射到Stargardt病患眼视网膜下腔,评估安全性。随访12个月,未发生眼部或全身炎症、排斥、肿瘤形成或毒性等不良事件,术后最佳矫正视力呈非显著性增加,结论认为该手术操作可行且安全。

要点

  • 人胚胎干细胞来源视网膜色素上皮细胞视网膜下腔注射用于Stargardt病,随访12个月未发生眼部或全身炎症、排斥、肿瘤形成或毒性。
  • 术后1年治疗眼最佳矫正视力呈非显著性增加,术中光学相干断层扫描对所有操作具有重要引导作用。
  • 该I期试验结论认为此手术操作可行且安全,随访期间无细胞迁移、排斥、炎症或眼部/全身肿瘤发生。

核心结论

  • 该手术操作可行且安全,随访期间无细胞迁移、排斥、炎症或眼部或全身肿瘤发生。

研究设计与样本

  • 前瞻性I期临床试验,将人胚胎干细胞来源视网膜色素上皮细胞悬液注射到最佳矫正视力较差眼的视网膜下腔。
  • 先行玻璃体切除/后玻璃体脱离,制作局限性视网膜脱离后给予人胚胎干细胞来源视网膜色素上皮细胞;有晶状体混浊眼行超声乳化联合人工晶状体植入。
  • 所有操作均在光学相干断层扫描引导下进行,随访12个月,包括视网膜影像、光学相干断层扫描、视野/电生理检查及全身评估。

主要发现

  • 超声乳化组与未行超声乳化组的基线平均最佳矫正视力相似,分别为1.950 ± 0.446和1.575 ± 0.303。
  • 术后1年,治疗眼最佳矫正视力呈非显著性增加。
  • 随访期间未发生不良事件。
  • 术中光学相干断层扫描对所有操作具有重要引导作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety of injecting human embryonic stem cell retinal pigment epithelial cell dose to treat Stargardt disease. METHODS: In this prospective, Phase I clinical trial, human embryonic stem cell retinal pigment epithelial cells in suspension were injected into the subretinal space in eyes with the worse best-corrected visual acuity (BCVA). After vitrectomy/posterior hyaloid removal, a partial retinal detachment was created and the human embryonic stem cell retinal pigment epithelial cells were administered. Phacoemulsification with intraocular lens implantation was performed in eyes with lens opacity. All procedures were optical coherence tomography-guided. The 12-month follow-up included retinal imaging, optical coherence tomography, visual field/electrophysiologic testing, and systemic evaluation. The main outcome was the absence of ocular/systemic inflammation or rejection, tumor formation, or toxicity during follow-up. RESULTS: The mean baseline BCVAs in the phacoemulsification and no phacoemulsification groups were similar (1.950 ± 0.446 and 1.575 ± 0.303, respectively). One year postoperatively, treated eyes showed a nonsignificant increase in BCVA. No adverse effects occurred during follow-up. Intraoperative optical coherence tomography was important for guiding all procedures. CONCLUSION: This surgical procedure was feasible and safe without cellular migration, rejection, inflammation, or development of ocular or systemic tumors during follow-up.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Brant Fernandes RA, Lojudice FH, Zago Ribeiro L, et al. TRANSPLANTATION OF SUBRETINAL STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM FOR STARGARDT DISEASE: A Phase I Clinical Trial. Retina. 2023. PMID: 36223778. doi:10.1097/IAE.0000000000003655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。